Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$24.80 USD
-0.17 (-0.68%)
Updated Aug 5, 2025 03:59 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHGCY 24.80 -0.17(-0.68%)
Will CHGCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHGCY
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
Chugai Pharmaceutical Co. (CHGCY) Upgraded to Buy: Here's Why
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Other News for CHGCY
Chugai Pharmaceutical reports Q2 results
Chugai Pharmaceutical Co., Ltd. 2025 Q2 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2025 Earnings Call Transcript
Harding Loevner Global Equity Q2 2025 Report
Chugai Pharmaceutical, Gero enter joint research, license agreement